31 Aug 2016
Lonza to Demonstrate Capabilities in Non-Viral or Viral CAR-T Research and Manufacturing at CAR-TCR Summit

Cologne (DE) / Walkersville, MD (USA), 31 August 2016 – Lonza will present its capabilities in supporting the development of viral and non-viral CAR-T cell therapies at the upcoming CAR-TCR Summit in Boston, MA) (USA) from 13-16 September. This presentation includes the introduction of the new 4D-Nucleofector™ LV Unit, the latest addition to the proven 4D-Nucleofector™ System, which expands highly efficient, non-viral primary T cell transfection to a closed, larger-scale format. Lonza's Nucleofector™ Technology improves on traditional electroporation methods to deliver enhanced transfection efficiencies while using less substrate and with only a moderate impact on cell viability.

The 4D-NucleofectorTM LV Unit complements Lonza's comprehensive CAR-T service offerings, which include custom development and manufacturing of viral therapy and large-scale GMP manufacture of CAR-T cells.

At the Lonza booth # 7, delegates can:

  • Discover the new 4D-Nucleofector™ LV Unit for large-scale transfection
  • Learn about Lonza's custom CAR-T services
  • Get a first glance of Lonza's innovative patient-scale manufacturing technologies
  • Find out about Lonza's serum-free media capabilities for hematopoietic cells

Lonza experts will also present on “Innovative Solutions for Manufacturing of Next-Generation Cell Therapies,” in which they will explore key topics such as overcoming manufacturing bottlenecks for CAR-T therapies, ensuring product quality and enabling commercially viable manufacturing through innovative platform technologies.

  • 2:40-3:10 pm, 14 September 2016 (in the Manufacturing Track)

“Lonza's Nucleofector™ Technology is an improved electroporation technique that has transformed transfection and allowed scientists to achieve results never possible before. The technology can particularly benefit those working with hard-to-transfect cell types, like primary blood cells or stem cells,” explained Herbert Mueller-Hartmann, Head of Research and Technology at Lonza. “The 4D-Nucleofector™ System was designed with the scientist in mind, so transfection protocols established on the existing smaller-scale unit can be smoothly transferred to the new large-scale unit without the need for re-optimization. The fully closed system is also suited for use in a regulatory environment as it can be controlled by 21 CFR Part 11-compatible software. The addition of this larger-scale transfection format allows us to accompany scientists as they translate the results of their research applications into potential therapeutic applications.”

Lonza provides the CAR-T market with end-to-end solutions for successful commercialization. These solutions include tools that can be used to develop and test therapeutics, ranging from cell culture and discovery technologies to quality control tests and process optimization. As a world-leading contract manufacturing organization (CMO), Lonza's manufacturing services can supply researchers with clinical-grade raw materials such as specialized media formulations and virus batches. Lonza's cellular manufacturing platforms remove supply bottlenecks and enable the CAR-T industry to provide commercially viable therapies at a global scale.

More information on how Lonza helps support the development and manufacture of viral and non-viral CAR-T cell therapies is available www.lonza.com/Car-T.